Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FuFang Danshen tablet after PCI for acute myocardial infarction
ChiCTR2300068681Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Guangzhou University of Chinese Medicine
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of fufang danshen tablet in myocardial infarction (MI) (2 arms), sponsored by First Affiliated Hospital of Guangzhou University of Chinese Medicine. Primary endpoints: Left ventricular ejection fraction and Minnesota Heart Failure scale score. Planned start Oct 2022; status: not yet recruiting.
02
Drugs
fufang danshen tablet
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on ChiCTR2300068681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300068681.